306 related articles for article (PubMed ID: 26070537)
1. Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.
Lian F; Zhou J; Wei C; Wang Y; Xu H; Liang L; Yang X
Clin Rheumatol; 2015 Nov; 34(11):1913-20. PubMed ID: 26070537
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
3. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
[TBL] [Abstract][Full Text] [Related]
4. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
[TBL] [Abstract][Full Text] [Related]
5. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
6. The clinical importance of the thyroid nodules during anti-tumor necrosis factor therapy in patients with axial spondyloarthritis.
Terlemez R; Akgün K; Palamar D; Boz S; Sarı H
Clin Rheumatol; 2017 May; 36(5):1071-1076. PubMed ID: 28357602
[TBL] [Abstract][Full Text] [Related]
7. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
8. Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France.
Soubrier M; Pereira B; Frayssac T; Abdi D; Couderc M; Daron C; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Clin Exp Rheumatol; 2016; 34(6):1059-1064. PubMed ID: 27607233
[TBL] [Abstract][Full Text] [Related]
9. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
10. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
Lee S; Park YJ; Lee JY
J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.
Kim M; Won JY; Choi SY; Ju JH; Park YH
Am J Ophthalmol; 2016 Oct; 170():32-40. PubMed ID: 27470062
[TBL] [Abstract][Full Text] [Related]
13. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.
Durnez A; Paternotte S; Fechtenbaum J; Landewé RB; Dougados M; Roux C; Briot K
J Rheumatol; 2013 Oct; 40(10):1712-8. PubMed ID: 23950191
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis.
Lee YH; Woo JH; Rho YH; Choi SJ; Ji JD; Song GG
Rheumatol Int; 2008 Apr; 28(6):553-9. PubMed ID: 17943257
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
19. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]